Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA appropriations

This article was originally published in The Tan Sheet

Executive Summary

President Clinton signs into law the FY 2000 Agriculture/FDA appropriations bill Oct. 22. The act provides FDA with a $1.18 bil. budget for the fiscal year (1"The Tan Sheet" Oct. 18, In Brief)

You may also be interested in...

FDA appropriations

Agency to receive $1.18 bil. in FY 2000 under the Agriculture/FDA appropriations bill approved by the Senate by a 74-26 vote Oct. 13. The House passed the measure (HR 1906) Oct. 1. President Clinton has said he will sign the legislation. The funding marks a $69 mil. increase over the agency's fiscal year 1999 budget, but is well below the President's request of $1.35 bil. CDER will receive $309 mil.; the Administration had requested $316 mil. for the drugs center. CFSAN and related field activities will get $269.2 mil. The bill requires the agency to submit a final rule on the "material time/material extent" standard on the use of foreign marketing data for sunscreens 60 days after passage (1"The Tan Sheet" Oct. 11, In Brief)

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

People In Brief

Perrigo promotes in pricing, planning





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts